2.03 Item 1 gives two different end dates for [product]'s orphan drug exclusivity in [indication]
Company G · a US-listed specialty pharmaceutical company · Presentation point
In brief
Item 1 states three times when the orphan drug exclusivity (ODE) for [product] in [indication] ends. The product section and the patents section say [date] ([date] plus [wording masked]), but the regulatory section says [date]. The same [date] sentence was in last year's Form 10-K. [product] is the company's largest product, and this exclusivity bears on when generic versions can be approved.
The evidence, as filed
8 further page extracts: screenshot withheld to protect the company’s identity. The rows below say what each shows.
What the filing shows, and what the rule requires
| What the filing shows | What the rule requires |
|---|---|
p.37: '[product] [wording masked] [indication] through [date]'; p.13 and p.28: through [date] | One date throughout Item 1: 'through [date] ([wording masked])' |
The rule
Regulation S-K Item 101(c)(1)
When describing each segment, only information material to an understanding of the business taken as a whole is required.
Version: Text in force at the date of this review · Source: Regulation S-K, 17 CFR 229.101(c)(1), as amended by Release 33-10825
Why it applies here. [date] is neither the original [date] expiry nor the extended [date] expiry, and it has been carried into a second annual report. The Form 10-Q for the quarter ended [date] again gives [date].
Why it matters
- A reader relying on the regulatory section would understate [product]'s [indication] exclusivity by a year.
- At most a staff comment asking for the dates to be reconciled; no figure is affected.
How often the SEC staff raises this. In 1,100 SEC staff comment letters on fiscal 2023 and 2024 Forms 10-K, released January 2025 to October 2026, business, properties and other Regulation S-K items drew 62 of the 1,774 numbered comments (3.5%): topic 8 of 25 by frequency.
Exposure
Low: a staff comment asking the company to reconcile the dates in future filings is the realistic consequence; no figure is affected.
Our workings
the product section says FDA recognized [wording masked] [product] in [indication] through [date], later extended to [date]; the patents section says through [date] including [wording masked]; the '[wording masked]' paragraph says through [date]. Last year's Form 10-K had both the [date] date and the same [date] sentence (its p.36). The risk factors and the MD&A of this 10-K also give [date], and the later Form 10-Q for the quarter ended [date] again gives [date].
[date] is neither the original [date] expiry nor the extended [date] expiry, so the regulatory paragraph is wrong and has been carried forward. Item 101(c)(1) asks for information material to an understanding of the business; the exclusivity of a product earning [n]% of net product sales is such information, so the three statements should agree.
Management’s best defense, and our reply
Management would say this is a typographical slip in a general regulatory paragraph, and that Item 1 gives the correct [date] date twice, including the precise day in the product section, so no reader is misled. They may add that the later Form 10-Q states the correct date. That reduces the weight but does not cure the point: the [date] sentence has now appeared unchanged in two consecutive annual reports, and it concerns the exclusivity of the product that earns [n]% of net product sales.
The fix
- In '[wording masked]', replace 'through [date]' with 'through [date] ([wording masked])'.
Evidence relied on
| # | What it shows | Type | Where |
|---|---|---|---|
| 1 | Regulatory section gives [date] as the end of [indication] exclusivity | Document | Form 10-K 2025, page 37 |
| 2 | Product section gives [date] extended to [date] | Document | Form 10-K 2025, page 13 |
| 3 | Patents section gives [date] including pediatric exclusivity | Document | Form 10-K 2025, page 28 |
| 4 | [product] is [n]% of net product sales, so its exclusivity period is material | Document | Form 10-K 2025, page 13 |
| 5 | Prior-year Form 10-K carried the same [date] sentence | Document | Form 10-K 2024 (prior year), page 36 |
| 6 | Later Form 10-Q (quarter ended [date]) confirms [date] | Document | |
| 7 | Last year's product section already gave the extended end date, [date]. | Document | Form 10-K 2024 (prior year), page 12 |
| 8 | Last year's patents section gave [date] as well. | Document | Form 10-K 2024 (prior year), page 27 |
| 9 | Last year's regulatory section gave [date] - the same two dates sat side by side in the fiscal 2024 Form 10-K. | Document | Form 10-K 2024 (prior year), page 36 |
Prepared by Pramanex from the company’s public SEC filings, without the company’s involvement, to show how a 10-K Pre-filing Check reads. The company is not named, and nothing on this page is a statement about any identifiable company. Observations are not an audit, review or other attestation or assurance engagement, and not legal advice. An SEC-style question is a question, not a conclusion.
Want this on your own 10-K, before you file?
Start with three free findings on your latest 10-K, or book a fixed-price 10-K Pre-filing Check.
Your next 10-K will be in draft before the audit is done.
Have it read before you file.
Start with three free findings on your latest 10-K, or book a fixed-price 10-K check. Drafts only under NDA, inside your insider trading policy.